<?xml version="1.0" encoding="utf-8"?><Protocol xmlns:msxsl="urn:schemas-microsoft-com:xslt" xmlns:scripts="urn:local-scripts"><p><Span Class="Protocol-Title">Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)</Span></p><p><a href="#StudyIdInfo"><Span Class="Protocol-TOC-Link">Basic Trial Information</Span></a><br /><a href="#TrialDescription"><Span Class="Protocol-TOC-Link">Trial Description</Span></a><br /><a href="#Summary"><Span Class="Protocol-TOC-SubLink">Summary</Span></a><br /><a href="#EntryCriteria"><Span Class="Protocol-TOC-SubLink">Eligibility Criteria</Span></a><br /><a href="#TrialContact"><Span Class="Protocol-TOC-Link">Trial Contact Information</Span></a><br /></p><a name="StudyIdInfo" /><P><Span Class="Protocol-Section-Heading">Basic Trial Information</Span></P><table width="556" cellspacing="0" cellpadding="1" border="0" class="Protocol-BasicStudy-Grayborder"><tr><td valign="top"><table width="554" cellspacing="0" cellpadding="0" border="0" bgcolor="#FFFFFF"><tr bgcolor="#E6E6E2"><td valign="top"><img src="/images/spacer.gif" width="4" height="21" alt="" border="0" /></td><td valign="middle"><Span Class="Protocol-BasicStudy-Heading">Phase</Span><Br /><img src="/images/spacer.gif" width="76" height="1" alt="" border="0" /></td><td valign="top"><img src="/images/spacer.gif" width="4" height="1" alt="" border="0" /></td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="8" height="1" alt="" border="0" /></td><td valign="middle" align="left"><Span Class="Protocol-BasicStudy-Heading">Type</Span><br /><img src="/images/spacer.gif" width="67" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="8" height="1" alt="" border="0" /></td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="8" height="1" alt="" border="0" /></td><td valign="middle" align="left"><Span Class="Protocol-BasicStudy-Heading">Status</Span><Br /><img src="/images/spacer.gif" width="57" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="8" height="1" alt="" border="0" /></td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="7" height="1" alt="" border="0" /></td><td valign="middle" align="left"><Span Class="Protocol-BasicStudy-Heading">Age Range (yrs)</Span><Br /><img src="/images/spacer.gif" width="104" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="8" height="1" alt="" border="0" /></td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="5" height="1" alt="" border="0" /></td><td valign="middle" align="left"><Span Class="Protocol-BasicStudy-Heading">
													Sponsor
												</Span><Br /><img src="/images/spacer.gif" width="69" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="5" height="1" alt="" border="0" /></td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="7" height="1" alt="" border="0" /></td><td valign="middle" align="left"><Span Class="Protocol-BasicStudy-Heading">Protocol IDs</Span><Br /><img src="/images/spacer.gif" width="90" height="1" alt="" border="0" /></td><td valign="middle"><img src="/images/spacer.gif" width="7" height="1" alt="" border="0" /></td></tr><tr><td valign="top" class="Protocol-BasicStudy-TD-Grayborder" colspan="23"><img src="/images/spacer.gif" width="554" height="1" alt="" border="0" /></td></tr><tr bgcolor="#FFFFFF"><td valign="top"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br />Phase II<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br />Treatment<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br />Closed<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br />18 and over<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br />Pharmaceutical/Industry<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td><td valign="top" class="Protocol-BasicStudy-TD-Grayborder"><img src="/images/spacer.gif" width="1" height="1" alt="" border="0" /></td><td valign="middle"> </td><td valign="top"><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /><Span Class="Protocol-BasicStudy-PrimaryID">Ipsen Protocol 2-91-52990-708</Span>, NCT00080015<Br /><img src="/images/spacer.gif" width="1" height="10" alt="" border="0" /><Br /></td><td valign="top"> </td></tr></table></td></tr></table><a name="TrialDescription"><P><Span Class="Protocol-Section-Heading">Trial Description</Span></P><a name="Summary" /><P><Span Class="Protocol-Section-SubHeading">Summary</Span></P>
    <a name="Section" /><P __id="">This is a Phase II, open-label, multicenter, single-arm, exploratory “proof of concept” study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.</P>
</a><a name="EntryCriteria"><P><Span Class="Protocol-Section-SubHeading">Eligibility Criteria</Span></P>
    <a name="Section" /><P __id="">Main Inclusion Criteria:</P>
    <a name="Section" /><a name="ListSection" /><UL __id="" class="Protocol-UL">
      <LI class="Protocol-IL-Bullet">Documented small cell lung cancer (SCLC)</LI>
    </UL><a name="END_ListSection" />
    <a name="Section" /><a name="ListSection" /><UL __id="" class="Protocol-UL">
      <LI class="Protocol-IL-Bullet">Measurable disease</LI>
    </UL><a name="END_ListSection" />
    <a name="Section" /><a name="ListSection" /><UL __id="" class="Protocol-UL">
      <LI class="Protocol-IL-Bullet">One line of previous chemotherapy, including any platinum analogue, and excluding any camptothecin analogues, with objective response and relapsed no less than 3 months</LI>
    </UL><a name="END_ListSection" />
    <a name="Section" /><P __id="">Main Exclusion Criteria:</P>
    <a name="Section" /><a name="ListSection" /><UL __id="" class="Protocol-UL">
      <LI class="Protocol-IL-Bullet">Uncontrollable brain metastasis</LI>
    </UL><a name="END_ListSection" />
    <a name="Section" /><a name="ListSection" /><UL __id="" class="Protocol-UL">
      <LI class="Protocol-IL-Bullet">Treated with an investigational drug within 30 days</LI>
    </UL><a name="END_ListSection" />
  </a><a name="Disclaimer"><div class="note">Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain 
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.</div><br /></a><a name="TrialContact" /><P><Span Class="Protocol-Section-Heading">Trial Contact Information</Span></P><a name="LeadOrgs"><P><Span Class="Protocol-Section-SubHeading">Trial Lead Organizations/Sponsors</Span></P><P><Span Class="Protocol-LeadOrg-OrgName">Beaufour Ipsen International SNC</Span></P>
    
    
    <table width="548" cellspacing="0" cellpadding="0" border="0"><tr><td valign="top" width="243"><Span Class="Protocol-LeadOrg-PersonName">Thierry Le Chevalier</Span><Span Class="Protocol-LeadOrg-Suffix">, MD</Span></td><td valign="top"><img src="/images/spacer.gif" width="10" height="1" alt="" border="0" /></td><td valign="top" width="295"><Span Class="Protocol-LeadOrg-PersonRole">Principal Investigator</Span></td></tr></table><Br />
  </a><a name="RequiredHeader"><P><a href="http://clinicaltrials.gov/show/NCT00080015">Link to the current ClinicalTrials.gov record.</a><Br /><Span Class="Protocol-NLMIdentifer">
					NLM Identifer NCT00080015</Span><Br /><Span Class="Protocol-DownloadDate">Information obtained from ClinicalTrials.gov on 2005-12-09</Span></P></a></Protocol>